Mineralys Therapeutics (MLYS) News Today $13.45 -0.02 (-0.15%) (As of 07/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period July 26 at 10:13 PM | marketbeat.comMineralys Therapeutics, Inc. (NASDAQ:MLYS) Director Brian Taylor Slingsby Sells 550,000 SharesMineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) Director Brian Taylor Slingsby sold 550,000 shares of the business's stock in a transaction that occurred on Wednesday, July 24th. The stock was sold at an average price of $13.05, for a total transaction of $7,177,500.00. Following the transaction, the director now owns 8,644,579 shares of the company's stock, valued at approximately $112,811,755.95. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.July 13, 2024 | insidertrades.comInsider Selling: Mineralys Therapeutics, Inc. (NASDAQ:MLYS) CFO Sells 10,757 Shares of StockJuly 12, 2024 | marketbeat.comMineralys Therapeutics, Inc. (NASDAQ:MLYS) CFO Adam Scott Levy Sells 10,757 SharesMineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) CFO Adam Scott Levy sold 10,757 shares of the business's stock in a transaction that occurred on Thursday, July 11th. The stock was sold at an average price of $13.14, for a total transaction of $141,346.98. Following the transaction, the chief financial officer now owns 247,611 shares of the company's stock, valued at approximately $3,253,608.54. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.July 12, 2024 | marketbeat.comMineralys Therapeutics (NASDAQ:MLYS) Shares Up 6.3%Mineralys Therapeutics (NASDAQ:MLYS) Shares Up 6.3%July 12, 2024 | marketbeat.comMineralys Therapeutics, Inc. (NASDAQ:MLYS) Expected to Post Q2 2024 Earnings of ($0.68) Per ShareMineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) - Investment analysts at HC Wainwright issued their Q2 2024 earnings estimates for shares of Mineralys Therapeutics in a research note issued to investors on Wednesday, July 10th. HC Wainwright analyst M. Caufield anticipates that the compaJuly 10, 2024 | marketbeat.comMineralys Therapeutics (NASDAQ:MLYS) Shares Gap Up to $12.89Mineralys Therapeutics (NASDAQ:MLYS) Shares Gap Up to $12.89June 15, 2024 | insidertrades.comInsider Selling: Mineralys Therapeutics, Inc. (NASDAQ:MLYS) CEO Sells 16,229 Shares of StockJune 14, 2024 | insidertrades.comInsider Selling: Mineralys Therapeutics, Inc. (NASDAQ:MLYS) CFO Sells 96,815 Shares of StockJune 14, 2024 | globenewswire.comMineralys Therapeutics Appoints Biopharmaceutical Executive Alexander M. Gold, M.D.June 11, 2024 | marketbeat.comMineralys Therapeutics (NASDAQ:MLYS) Stock Price Down 5.2%Mineralys Therapeutics (NASDAQ:MLYS) Trading Down 5.2%June 9, 2024 | marketbeat.comCatalys Pacific LLC Takes $79.07 Million Position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS)Catalys Pacific LLC bought a new stake in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 9,194,579 shares of the company's stock, valued atJune 8, 2024 | marketbeat.comSectoral Asset Management Inc. Lowers Stock Position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS)Sectoral Asset Management Inc. lowered its position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 28.0% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 605,606 shares of the company's stock after selling 235,153 shares during theJune 1, 2024 | marketbeat.comMineralys Therapeutics, Inc. (NASDAQ:MLYS) Shares Purchased by Franklin Resources Inc.Franklin Resources Inc. boosted its stake in Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 55.4% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 699,467 shares of the company's stock after purchasing an additional 249,450 shares during the period.May 13, 2024 | markets.businessinsider.comBank of America Securities Reaffirms Their Buy Rating on Mineralys Therapeutics, Inc. (MLYS)May 13, 2024 | finance.yahoo.comMineralys Therapeutics, Inc. (NASDAQ:MLYS) Q1 2024 Earnings Call TranscriptMay 10, 2024 | markets.businessinsider.comMineralys Therapeutics: Strong Buy on Upcoming ADVANCE Trial Results and Robust Financial HealthMay 10, 2024 | marketbeat.comMineralys Therapeutics (NASDAQ:MLYS) Stock Price Down 4.6%Mineralys Therapeutics (NASDAQ:MLYS) Shares Down 4.6%May 9, 2024 | msn.comMineralys Therapeutics GAAP EPS of -$0.70 misses by $0.03May 9, 2024 | globenewswire.comMineralys Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 6, 2024 | marketbeat.comMineralys Therapeutics (NASDAQ:MLYS) Sees Unusually-High Trading VolumeMineralys Therapeutics (NASDAQ:MLYS) Sees Strong Trading VolumeMay 6, 2024 | globenewswire.comMineralys Therapeutics to Participate in the Bank of America Securities Health Care ConferenceMay 3, 2024 | marketbeat.comMineralys Therapeutics (MLYS) to Release Quarterly Earnings on ThursdayMineralys Therapeutics (NASDAQ:MLYS) will be releasing earnings before the market opens on Thursday, May 9, Zacks reports.May 3, 2024 | msn.comMineralys Therapeutics to Unveil First Quarter Financial ResultsMay 2, 2024 | globenewswire.comMineralys Therapeutics to Announce First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 9, 2024April 18, 2024 | marketbeat.comMineralys Therapeutics (NASDAQ:MLYS) Shares Down 3.7% Mineralys Therapeutics (NASDAQ:MLYS) Trading Down 3.7%April 2, 2024 | msn.comGoldman starts Mineralys at buy, cites upcoming drug dataApril 2, 2024 | marketbeat.comMineralys Therapeutics (NASDAQ:MLYS) Coverage Initiated at The Goldman Sachs GroupThe Goldman Sachs Group initiated coverage on Mineralys Therapeutics in a research report on Tuesday. They issued a "buy" rating and a $30.00 target price on the stock.March 28, 2024 | marketbeat.comAnalysts Issue Forecasts for Mineralys Therapeutics, Inc.'s FY2024 Earnings (NASDAQ:MLYS)Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) - Stock analysts at Lifesci Capital issued their FY2024 earnings estimates for Mineralys Therapeutics in a research note issued to investors on Tuesday, March 26th. Lifesci Capital analyst R. Katkhuda expects that the company will earn ($2.March 28, 2024 | marketbeat.comLifesci Capital Reiterates Outperform Rating for Mineralys Therapeutics (NASDAQ:MLYS)Lifesci Capital reissued an "outperform" rating on shares of Mineralys Therapeutics in a research report on Tuesday.March 27, 2024 | marketbeat.comMineralys Therapeutics (NASDAQ:MLYS) Shares Gap Up to $12.84Mineralys Therapeutics (NASDAQ:MLYS) Shares Gap Up to $12.84March 22, 2024 | markets.businessinsider.comBuy Rating Affirmed for Mineralys Therapeutics Amid Positive Clinical and Strategic DevelopmentsMarch 22, 2024 | finance.yahoo.comMineralys Therapeutics, Inc. (NASDAQ:MLYS) Q4 2023 Earnings Call TranscriptMarch 21, 2024 | msn.comMineralys Therapeutics files for $500M mixed shelf offeringMarch 21, 2024 | finance.yahoo.comMineralys Therapeutics Inc (MLYS) Reports Increased R&D Expenses Amid Progress in ...March 21, 2024 | marketbeat.comMineralys Therapeutics (NASDAQ:MLYS) Trading Down 4.7%Mineralys Therapeutics (NASDAQ:MLYS) Stock Price Down 4.7%March 21, 2024 | seekingalpha.comMineralys Therapeutics, Inc. 2023 Q4 - Results - Earnings Call PresentationMarch 21, 2024 | globenewswire.comMineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateMarch 20, 2024 | finance.yahoo.comMLYS Jun 2024 12.500 callMarch 20, 2024 | finance.yahoo.comMLYS Sep 2024 30.000 callMarch 20, 2024 | benzinga.comMineralys Therapeutics Earnings PreviewMarch 19, 2024 | marketbeat.comMineralys Therapeutics (NASDAQ:MLYS) Shares Up 4.7%Mineralys Therapeutics (NASDAQ:MLYS) Stock Price Up 4.7%March 18, 2024 | msn.comMineralys Therapeutics Set to Release Q4 and Full-Year 2023 Financial Results, Eyes on Future Growth ProspectsMarch 18, 2024 | seekingalpha.comMineralys Therapeutics: A Story To Keep An Eye OnMarch 16, 2024 | finance.yahoo.comMLYS Apr 2024 15.000 callMarch 16, 2024 | finance.yahoo.comMLYS Mar 2024 20.000 callMarch 13, 2024 | globenewswire.comMineralys Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on Thursday, March 21, 2024March 9, 2024 | marketbeat.comMineralys Therapeutics, Inc. (NASDAQ:MLYS) Shares Acquired by Schonfeld Strategic Advisors LLCSchonfeld Strategic Advisors LLC increased its stake in Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 64.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 192,362 sharesMarch 7, 2024 | marketbeat.comMineralys Therapeutics, Inc. (NASDAQ:MLYS) Position Increased by Fmr LLCFmr LLC increased its stake in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 62.6% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,188,653 shares of the company's stock after buyMarch 4, 2024 | benzinga.comMineralys Therapeutics Stock (NASDAQ:MLYS) Dividends: History, Yield and DatesMarch 1, 2024 | marketbeat.comBraidwell LP Purchases 1,473,600 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS)Braidwell LP grew its stake in Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 267.8% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,023,900 shares of the company's stock after purchasing an additional 1,473,60 Get Mineralys Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MLYS and its competitors with MarketBeat's FREE daily newsletter. Email Address This TSLA short trade is on a nine win hot streak (Ad)Most Tesla Shareholders are disappointed in the stock's performance in 2024. Year to date, it's down 30%... And things don’t seem to be getting better. That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity… In fact, he has not lost a single trade on Tesla this year. As of this mailing he’s 9 for 9 with incredible wins under his belt. Just see for yourself. But I can promise that you’ll see all the details for yourself here. MLYS Media Mentions By Week MLYS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MLYS News Sentiment▼0.380.62▲Average Medical News Sentiment MLYS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MLYS Articles This Week▼41▲MLYS Articles Average Week Get Mineralys Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MLYS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: PTCT News Today JANX News Today AMRX News Today RCKT News Today PTGX News Today DCPH News Today MRVI News Today CPRX News Today ARVN News Today EWTX News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MLYS) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored4 Steps to Survive the Coming Market CrashCracks threaten us with a widespread collapse unlike anything we've seen in our lifetime. During this prese...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mineralys Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mineralys Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
